Electronic symptom monitoring improves chemotherapy dose intensity in neoadjuvant chemotherapy for breast cancer

IF 2.4 4区医学 Q3 ONCOLOGY

Current Problems in Cancer Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI:10.1016/j.currproblcancer.2025.101266

Yuki Takei , Atsufumi Nomoto , Mizuki Kawashima , Yuko Miyake , Arisa Kawakami , Tadamitsu Shima , Isao Teshima , Natsumi Nomoto , Yoshiharu Mitsunaga , Tamaki Watanabe , Yukie Nagase , Nobuhiro Yasuno

{"title":"Electronic symptom monitoring improves chemotherapy dose intensity in neoadjuvant chemotherapy for breast cancer","authors":"Yuki Takei , Atsufumi Nomoto , Mizuki Kawashima , Yuko Miyake , Arisa Kawakami , Tadamitsu Shima , Isao Teshima , Natsumi Nomoto , Yoshiharu Mitsunaga , Tamaki Watanabe , Yukie Nagase , Nobuhiro Yasuno","doi":"10.1016/j.currproblcancer.2025.101266","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The present study investigated the clinical impact of electronic patient-reported outcome (ePRO) monitoring on chemotherapy dose intensities and adverse event (AE) management in patients with early-stage breast cancer receiving neoadjuvant chemotherapy.</div></div><div><h3>Methods</h3><div>In this single-center retrospective study, conducted between October 2022 and June 2024, we compared outcomes between patients treated with and without ePRO monitoring during neoadjuvant chemotherapy. The primary endpoint was the percentage of patients who achieved an average relative dose intensity (ARDI) of ≥85 %. The secondary endpoint was the persistence of grade ≥2 non-hematologic AEs, defined as symptoms that remained unresolved (i.e., not improved to grade ≤1) by the start of the subsequent chemotherapy cycle. Follow-ups continued until October 31, 2024.</div></div><div><h3>Results</h3><div>Ninety-six patients were analyzed (ePRO group, <em>n</em> = 42; usual care group, <em>n</em> = 54). The percentage of patients achieving ARDI ≥85 % was significantly higher in the ePRO group than in the usual care group (85.7 % vs. 66.7 %, <em>p</em> = 0.029). The persistence of non-hematologic AEs was significantly lower in the ePRO group (<em>p</em> = 0.002). A multivariate analysis confirmed that ePRO use was independently associated with ARDI ≥85 % (odds ratio [OR], 4.05; 95 % confidence interval [CI], 1.04–15.8; <em>p</em> = 0.045) and reduced AE persistence (OR, 0.08; 95 % CI, 0.01–0.49; <em>p</em> = 0.002).</div></div><div><h3>Conclusion</h3><div>ePRO monitoring may help to maintain chemotherapy dose intensities and shorten the duration of AEs in early-stage breast cancer patients receiving neoadjuvant chemotherapy.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"60 ","pages":"Article 101266"},"PeriodicalIF":2.4000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027225000935","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The present study investigated the clinical impact of electronic patient-reported outcome (ePRO) monitoring on chemotherapy dose intensities and adverse event (AE) management in patients with early-stage breast cancer receiving neoadjuvant chemotherapy.

Methods

In this single-center retrospective study, conducted between October 2022 and June 2024, we compared outcomes between patients treated with and without ePRO monitoring during neoadjuvant chemotherapy. The primary endpoint was the percentage of patients who achieved an average relative dose intensity (ARDI) of ≥85 %. The secondary endpoint was the persistence of grade ≥2 non-hematologic AEs, defined as symptoms that remained unresolved (i.e., not improved to grade ≤1) by the start of the subsequent chemotherapy cycle. Follow-ups continued until October 31, 2024.

Results

Ninety-six patients were analyzed (ePRO group, n = 42; usual care group, n = 54). The percentage of patients achieving ARDI ≥85 % was significantly higher in the ePRO group than in the usual care group (85.7 % vs. 66.7 %, p = 0.029). The persistence of non-hematologic AEs was significantly lower in the ePRO group (p = 0.002). A multivariate analysis confirmed that ePRO use was independently associated with ARDI ≥85 % (odds ratio [OR], 4.05; 95 % confidence interval [CI], 1.04–15.8; p = 0.045) and reduced AE persistence (OR, 0.08; 95 % CI, 0.01–0.49; p = 0.002).

Conclusion

ePRO monitoring may help to maintain chemotherapy dose intensities and shorten the duration of AEs in early-stage breast cancer patients receiving neoadjuvant chemotherapy.

Abstract Image

查看原文本刊更多论文

电子症状监测提高乳腺癌新辅助化疗剂量强度。

目的：本研究探讨电子患者报告预后（ePRO）监测对早期乳腺癌新辅助化疗患者化疗剂量强度和不良事件（AE）处理的临床影响。方法：在这项于2022年10月至2024年6月进行的单中心回顾性研究中，我们比较了在新辅助化疗期间接受和未接受ePRO监测的患者的结果。主要终点是达到平均相对剂量强度(ARDI)≥85%的患者百分比。次要终点是持续≥2级非血液学ae，定义为在随后的化疗周期开始时症状仍未解决（即未改善到≤1级）。随访一直持续到2024年10月31日。结果：共分析96例患者，其中ePRO组42例，常规护理组54例。ePRO组达到ARDI≥85%的患者比例显著高于常规护理组（85.7% vs. 66.7%, p = 0.029）。ePRO组非血液学ae的持续时间显著降低（p = 0.002）。多因素分析证实，ePRO的使用与ARDI≥85%（优势比[OR]， 4.05； 95%可信区间[CI]， 1.04-15.8; p = 0.045）和AE持续性降低独立相关（OR, 0.08; 95% CI, 0.01-0.49; p = 0.002）。结论：ePRO监测有助于早期乳腺癌新辅助化疗患者维持化疗剂量强度，缩短ae持续时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cancer 医学-肿瘤学

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

15 days

期刊介绍： Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.